Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CEBPA-51||Phase I||Actionable||In a Phase I trial, CEBPA-51 treatment demonstrated safety and preliminary efficacy, resulted in increased Cebpa expression in WBC in patients with advanced solid tumors, including hepatocellular carcinoma, colorectal, and fibrolamellar cancer (J Clin Oncol, 36(no. 15_suppl), May 2018, 2509-2509; NCT02716012).||detail...|
|PubMed Id||Reference Title||Details|
|Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-? in patients with advanced liver cancer.||Full reference...|